Skip to content
New Options

You Are Empowered To Save More Limbs

Lifechanging technology is giving new hope to no-option CLTI patients

As a medical practitioner, you understand the pressing need for effective, long-lasting treatment options for patients in the advanced stages of peripheral artery disease. You may have experienced frustration with the limited treatment options available for these patients, who are at risk of major lower limb amputation, with its associated low quality of life and high mortality rate.

At LimFlow, we are committed to providing an innovative therapy that can help reduce the major amputation rate, heal non-healing wounds, and improve patient outcomes. We believe that every limb saved is victory, and with LimFlow, you have the opportunity to transform the lives of your patients. Through collaboration with leading industry experts, we have pioneered groundbreaking approaches to managing end-stage peripheral artery disease.”

Senior African American Couple Walking Through Fall Woodland

Our LimFlow System for Transcatheter Arterialization of Deep Veins (TADV) is a groundbreaking innovation that can transform the way you approach patient care, providing them with an opportunity for a better quality of life.

Learn About the Technology

The LimFlow System is designed to restore blood flow to the ischemic foot when all Chronic Limb-Threatening Ischemia (CLTI) treatment options have been exhausted, promoting healing of chronic wounds, improving patients’ quality of life and getting them back to the things they love

LimFlow-022-hi (1)
Limflow V-Ceiver
LimFlow-Valvulotome Flip

How it Works: Permanently Bypasses Unreconstructable Arteries

Before LimFlow

Healthcare Professionals

After LimFlow

Healthcare Professionals

See the LimFlow System In Action

Clinical Evidence

LimFlow is a pioneer in the development of minimally-invasive technology for the treatment of chronic limb-threatening ischemia (CLTI), a severe form of peripheral artery disease (PAD).

Review our unprecedented clinical results for your most challenging patients.

See PROMISE II 6 Month results in The New England Journal of Medicine. 

Hear From Your Peers